BTSG Stock Analysis: BrightSpring Health | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 11.917m USD | 12M Return: 145.7% | US10950A1060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 165M
Qual. Beats: 3
Rev. Trend: 99.7%
Qual. Beats: 6
Warnings
Tailwinds
Seasonality 2.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BrightSpring Health Services, Inc. (NASDAQ: BTSG) is a US-based home and community-based healthcare services platform that operates through two segments: Pharmacy Solutions and Provider Services. The company serves Medicare, Medicaid, and insured populations, delivering clinical and supportive care in home and community settings.
Its Pharmacy Solutions segment provides infused, injectable, and oral medication services, while its Provider Services segment offers home health care along with rehabilitation services such as physical, speech, and occupational therapy, as well as applied behavioral analysis. The company was founded in 1974 and is headquartered in Louisville, Kentucky. It was formerly known as Phoenix Parent Holdings Inc. before adopting its current name in May 2021, and completed its initial public offering on January 26, 2024.
BrightSprings integrated model combining specialty pharmacy and clinical provider services under one platform is relatively uncommon in the home and community-based care sector, an area of healthcare that has grown steadily alongside aging populations and a broader shift toward in-home care settings over facility-based treatment.
- Medicare home health payment rate revisions pressure Provider Services margins
- Pharmacy Solutions revenue grows on specialty infusion and injectable drug demand
- Labor cost inflation pressures clinician and pharmacist wage expenses
- Acquisition strategy expands community-based health service platform
| Net Income: 294.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.51 > 1.0 |
| NWC/Revenue: 6.36% < 20% (prev 9.53%; Δ -3.17% < -1%) |
| CFO/TA 0.08 > 3% & CFO 506.4m > Net Income 294.0m |
| Net Debt (2.03b) to EBITDA (638.9m): 3.18 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (220.3m) vs 12m ago 1.82% < -2% |
| Gross Margin: 12.38% > 18% (prev 12.88%; Δ -0.49% > 0.5%) |
| Asset Turnover: 240.9% > 50% (prev 201.7%; Δ 39.29% > 0%) |
| Interest Coverage Ratio: 3.14 > 6 (EBIT TTM 478.1m / Interest Expense TTM 152.3m) |
| A: 0.15 (Total Current Assets 2.47b - Total Current Liabilities 1.56b) / Total Assets 5.99b |
| B: 0.01 (Retained Earnings 38.4m / Total Assets 5.99b) |
| C: 0.08 (EBIT TTM 478.1m / Avg Total Assets 5.96b) |
| D: 0.52 (Book Value of Equity 2.05b / Total Liabilities 3.93b) |
| Altman-Z'' = 2.11 = BBB |
| DSRI: 1.02 (Receivables 1.31b/1.07b, Revenue 14.4b/12.0b) |
| GMI: 1.04 (GM 12.88% / 12.38%) |
| AQI: 1.05 (AQ_t 0.52 / AQ_t-1 0.50) |
| SGI: 1.20 (Revenue 14.4b / 12.0b) |
| TATA: -0.04 (NI 294.0m - CFO 506.4m) / TA 5.99b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of August 22, 2026, the stock is trading at USD 58.87 with a total of 1,523,715 shares traded. Over the past week, the price has changed by -4.60%, over one month by -18.87%, over three months by +1.52% and over the past year by +145.70%.
Current recommended Stop Loss: 55.10 (which is 6.4% or 1.3 ATR below the current price).
BrightSpring Health has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy BTSG.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 78.9 | 34.1% |
P/E Trailing = 53.7768
P/E Forward = 31.8471
P/S = 0.8496
P/B = 5.5929
Revenue TTM = 14.4b USD
EBIT TTM = 478.1m USD
EBITDA TTM = 638.9m USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 93.0m USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 196.9m
Net Debt = 2.03b USD (calculated: Debt 2.58b - CCE 550.4m)
Enterprise Value = 14.0b USD (11.9b + Debt 2.58b - CCE 550.4m)
Interest Coverage Ratio = 3.14 (Ebit TTM 478.1m / Interest Expense TTM 152.3m)
EV/FCF = 34.68x (Enterprise Value 14.0b / FCF TTM 402.4m)
FCF Yield = 2.88% (FCF TTM 402.4m / Enterprise Value 14.0b)
FCF Margin = 2.80% (FCF TTM 402.4m / Revenue TTM 14.4b)
Net Margin = 2.05% (Net Income TTM 294.0m / Revenue TTM 14.4b)
Gross Margin = 12.38% ((Revenue TTM 14.4b - Cost of Revenue TTM 12.6b) / Revenue TTM)
Gross Margin QoQ = 12.72% (prev 13.34%)
Tobins Q-Ratio = 2.33 (Enterprise Value 14.0b / Total Assets 5.99b)
Interest Expense / Debt = 5.89% (Interest Expense 152.3m / Debt 2.58b)
Taxrate = 16.11% (47.6m / 295.5m)
NOPAT = 401.1m (EBIT 478.1m * (1 - 16.11%))
Current Ratio = 1.59 (Total Current Assets 2.47b / Total Current Liabilities 1.56b)
Debt / Equity = 1.26 (Debt 2.58b / totalStockholderEquity, last quarter 2.05b)
Debt / EBITDA = 3.18 (Net Debt 2.03b / EBITDA 638.9m)
Debt / FCF = 5.06 (Net Debt 2.03b / FCF TTM 402.4m)
Total Stockholder Equity = 1.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.93% (Net Income 294.0m / Total Assets 5.99b)
RoE = 15.23% (Net Income TTM 294.0m / Total Stockholder Equity 1.93b)
RoCE = 11.72% (EBIT 478.1m / Capital Employed (Equity 1.93b + L.T.Debt 2.15b))
RoIC = 10.10% (NOPAT 401.1m / Invested Capital 3.97b)
WACC = 9.14% (E(11.9b)/V(14.5b) * Re(10.05%) + D(2.58b)/V(14.5b) * Rd(5.89%) * (1-Tc(0.16)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.30 | Cagr: 10.62%
[DCF] Terminal Value 75.45% ; FCFF base≈317.9m ; Y1≈364.4m ; Y5≈536.3m
[DCF] Fair Price = 25.53 (EV 7.09b - Net Debt 2.03b = Equity 5.05b / Shares 197.9m; r=9.14% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.48 | # QB: 3
Revenue Correlation: 99.73 | Revenue CAGR: 22.09% | SUE: 1.63 | # QB: 6
EPS current Quarter (2026-09-30): EPS=0.47 | Chg30d=+7.70% | Revisions=+80% | Analysts=16
EPS current Year (2026-12-31): EPS=1.82 | Chg30d=+7.69% | Revisions=+77% | GrowthEPS=+81.9% | GrowthRev=+19.0%
EPS next Year (2027-12-31): EPS=2.28 | Chg30d=+7.22% | Revisions=+82% | GrowthEPS=+25.2% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: +92% (up=36, down=0)